- Report
- August 2025
- 150 Pages
Global
From €2990EUR$3,358USD£2,609GBP
€3518EUR$3,950USD£3,070GBP
- Report
- August 2025
- 198 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- August 2025
- 194 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- August 2025
- 191 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 197 Pages
Global
From €5210EUR$5,850USD£4,547GBP
- Report
- October 2025
- 250 Pages
Global
From €3998EUR$4,490USD£3,490GBP
- Report
- October 2025
- 250 Pages
Global
From €3998EUR$4,490USD£3,490GBP
- Report
- October 2025
- 250 Pages
Global
From €3998EUR$4,490USD£3,490GBP
- Report
- April 2025
- 200 Pages
Global
From €3998EUR$4,490USD£3,490GBP
- Report
- April 2025
- 200 Pages
Global
From €3998EUR$4,490USD£3,490GBP
- Report
- March 2025
- 200 Pages
Global
From €3998EUR$4,490USD£3,490GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2137EUR$2,400USD£1,865GBP
€2672EUR$3,000USD£2,332GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €891EUR$1,000USD£777GBP
€1113EUR$1,250USD£972GBP
- Report
- May 2025
- 183 Pages
Global
From €4007EUR$4,500USD£3,497GBP
- Report
- January 2025
- 140 Pages
Global
From €3518EUR$3,950USD£3,070GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2484EUR$2,789USD£2,168GBP
- Report
- June 2025
- 400 Pages
Global
From €4407EUR$4,949USD£3,846GBP
- Report
- March 2025
- 1400 Pages
Global
From €4364EUR$4,900USD£3,808GBP
- Report
- March 2025
- 145 Pages
Global
From €3671EUR$4,123USD£3,204GBP
€4319EUR$4,850USD£3,769GBP
- Report
- March 2025
- 260 Pages
Middle East
From €2583EUR$2,900USD£2,254GBP

Alpha Glucosidase Inhibitors are a class of drugs used to treat Endocrine and Metabolic Disorders. These drugs work by inhibiting the enzyme alpha-glucosidase, which is responsible for breaking down carbohydrates in the small intestine. This helps to reduce the amount of glucose absorbed into the bloodstream, which can help to control blood sugar levels. Alpha Glucosidase Inhibitors are commonly used to treat type 2 diabetes, as well as other conditions such as polycystic ovary syndrome and gestational diabetes.
Alpha Glucosidase Inhibitors are available in both oral and injectable forms. Common side effects of these drugs include abdominal pain, nausea, and diarrhea. Long-term use of these drugs can also lead to an increased risk of hypoglycemia.
Some companies that produce Alpha Glucosidase Inhibitors include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more